Novel Bispecific Antibody Nets Durable Remissions in Follicular Lymphoma Mosunetuzumab offers "clinically meaningful outcomes" in relapsed/refractory disease Dec 12, 2021
Induction Isatuximab-RVd Combo Boosts MRD Negativity in Multiple Myeloma Half of newly diagnosed, transplant-eligible patients reached minimal residual disease negativity Dec 12, 2021
CAR T-Cell Therapy Makes Strong Case for Earlier Use in Lymphoma Large increases in event-free survival with two CAR T-cell products in second line Dec 11, 2021
Upfront IDH1 Inhibitor Triples Survival in Older AML Median OS for ivosidenib-azacitidine reached 2 years in patients ineligible for intensive therapy Dec 11, 2021
Case of Parkinson's-Like Symptoms in Myeloma Patient After CAR-T Product FDA advises monitoring patients after T-cell infusion for signs, symptoms of neurotoxicity Dec 10, 2021
'Watch and Switch' Strategy Extends PFS in HR-Positive Breast Cancer Progression-free survival doubled with treatment change based on monitoring for resistance marker Dec 10, 2021
CDK7 Inhibitor-Based Combo Promising in CDK4/6-Resistant Breast Cancer Clinical benefit rate of 36%, plus tumor shrinkage, with samuraciclib plus fulvestrant Dec 10, 2021
Pyrotinib Tops Lapatinib in Metastatic HER2-Positive Breast Cancer Updated PHOEBE trial results now show an overall survival benefit as well Dec 10, 2021
Ethics Consult: Should Doctor Inform Patient's Family of Diagnosis? MD/JD Weighs In You voted, now see the results and an expert's discussion Dec 10, 2021
Benefits of Ovarian Suppression Persist in Premenopausal Breast Cancer Aromatase inhibitor-ovarian suppression tops tamoxifen strategies at 12-13 years Dec 09, 2021
Highly Mutated Breast Cancer Responds to Immunotherapy Nivolumab-ipilimumab combination associated with durable response in small study Dec 09, 2021
Ribociclib's OS Benefit in Breast Cancer Seen Regardless of Metastatic Site Second analysis shows OS benefit consistent across some intrinsic subtypes as well Dec 09, 2021
No Benefit With Metformin in Early Breast Cancer, Regardless of ER/PR Status However, there could be improved outcomes in HER2-positive patients Dec 08, 2021
Small PFS Boost With HDAC Inhibitor for Advanced HR-Positive Breast Cancer Chinese study contradicts U.S. trial that showed no benefit with entinostat add-on Dec 08, 2021
Black Women Most at Risk for Post-Surgical Lymphedema Black women seemed to have triple the odds of swelling after axillary lymph node dissection Dec 08, 2021
TROP2-Directed ADC Promising in Advanced Triple-Negative Breast Cancer Datopotamab deruxtecan turns in solid phase I results Dec 08, 2021
BRAF Inhibition in Pediatric Ameloblastoma of the Jaw Targeted therapy in 3 boys allowed for conservative surgery to restore jaw to predisease state Dec 07, 2021
Hemostatic Powder on Par for Stopping Acute Upper GI Bleeds In non-inferiority trial, TC-325 matched standard therapy for nonvariceal lesions Dec 07, 2021
Genomic Profiling Improves Outcomes in Breast Cancer PFS was better when targeted treatment for genomic alterations was supported by ESCAT criteria Dec 07, 2021
But the Cancer Was 'Indolent' Tread carefully when offering patients an optimistic outlook Dec 07, 2021
Novel Endocrine Drug Slows Previously Treated HR-Positive Breast Cancer Elacestrant led to significant improvement in all patients, ESR1-mutant subgroup Dec 07, 2021
Novel Chemoimmunotherapy Regimen Wows in Pediatric Neuroblastoma "I've never seen anything like this," researcher says of 3-year event-free survival rate Dec 06, 2021
Bevacizumab Add-On No Help in Progressive EGFR-Mutant Lung Cancer Single-agent osimertinib prevails in progressive, T790M-positive NSCLC Dec 02, 2021
Artificial Intelligence Tool Gets High Marks in Reading Mammograms Breast cancer screening results show AI's mettle in real-world dataset Dec 02, 2021
States Didn't Follow CDC Recs to Prioritize COVID Vaccine for Cancer Patients Only 17 states gave cancer patients the same immunization priority as those ages 65-74 Dec 02, 2021
Long-Term Data Reinforce Standard of Care in Unresectable Melanoma Landmark trial shows median OS of 72.1 months with nivolumab-ipilimumab Dec 01, 2021
NCCN Reverses on Guideline Change for Surveillance in Prostate Cancer Active surveillance again preferred choice for "most" men with low-risk disease Dec 01, 2021
Next-Gen MRD Testing Predicts Acute Leukemia Relapse After CAR-T Nearly all patients with detectable disease relapsed or progressed to transplant, other therapies Dec 01, 2021
Chemo-Free Regimen Highly Active in Older Mantle Cell Lymphoma Patients Overall response rate of 96% with ibrutinib-rituximab, but cardiotoxicity a possible issue Nov 29, 2021
Novel Triplet Yields Undetectable MRD Status in 90% of CLL/SLL Patients Zanubrutinib plus obinutuzumab and venetoclax was also well tolerated Nov 29, 2021
'Actual' 5-Year Survival Rate of 27% After Surgery, Chemo for Pancreatic Cancer Fewer than half of the survivors remained recurrence- or disease-free Nov 19, 2021
Year in Review: Prostate Cancer PSMA-targeted imaging agent approvals, MRI-targeted biopsies, and genomic testing Nov 19, 2021
FDA OKs PD-1 Inhibitor for Adjuvant Treatment of Kidney Cancer Key trial showed 32% reduction in risk of recurrence with pembrolizumab Nov 18, 2021
Ceritinib Shows Promise in ALK-Positive Pediatric Malignancies Responses seen in neuroblastoma, among other tumors Nov 17, 2021
Tumor Spill Common in Minimally Invasive Hysterectomies for Endometrial Cancer Few surgeons in survey reported changing post-op management after spillage Nov 16, 2021
Year in Review: HER2-Positive Breast Cancer ADCs impress in second-line therapy, primary surgery debate, neoadjuvant PD-L1 falls short Nov 15, 2021
Pegylated Interferon Wins FDA Approval for Polycythemia Vera Majority of patients attained complete hematologic response with ropeginterferon alfa-2b Nov 15, 2021
Chemo-ICI Combo Promising in Soft Tissue Sarcoma PFS rate of 69% at 12 weeks in liposarcoma patients with eribulin and pembrolizumab Nov 14, 2021
Active Surveillance Still the Best Bet in Desmoid-Type Fibromatosis GRAFITI trial show's less than a third of watched patients eventually need active treatment Nov 13, 2021
Just How Bad Is a 'Sulfur Microbial Diet' for Colorectal Cancer Risk? Risk for CRC increased by 27% in healthcare workers who consumed the highest amounts Nov 12, 2021
